India first choice for knowledge process outsourcing

By Kirsty Barnes

- Last updated on GMT

Related tags: Business process outsourcing, India

India is the first choice for foreign companies looking to offshore
their knowledge process outsourcing (KPO) activities and future
growth will be fuelled by the pharma market, according to a new

The country has the largest pool of KPO-capable manpower, produces more than 3m graduates annually and harbours the second biggest reservoir of scientists, managers, and engineers in the world. As a result, India's KPO industry has generated over 250,000 jobs over the past five years and is expected to easily capture 15 per cent of the world's KPO business by 2010, according to "KPO - The New Outsourcing Avenue for Indian BPO Market"​, a market research report by RNCOS. "By far, India is the most sought after KPO destination for foreign companies thanks to the competitive salaries and large number of proficient professionals,"​ the report said. Over the next few years, however, the technically advanced segments of the KPO industry surrounding pharma R&D are tipped to achieve particularly tremendous growth. Along with the data and market research segment, pharma KPO is expected to make up 50 per cent India's KPO business in the future, predicts the report.

Related news

Show more

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more